JP Morgan Chase’s SpringWorks Therapeutics SWTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,148,914
| Closed | -$54M | – | 7714 |
|
|
2025
Q2 | $54M | Buy |
1,148,914
+1,086,550
| +1,742% | +$48.3M | ﹤0.01% | 1288 |
|
|
2025
Q1 | $2.75M | Sell |
62,364
-165,571
| -73% | -$7.62M | ﹤0.01% | 3624 |
|
|
2024
Q4 | $8.24M | Sell |
227,935
-27,117
| -11% | -$947K | ﹤0.01% | 2880 |
|
|
2024
Q3 | $8.17M | Sell |
255,052
-25,074
| -9% | -$937K | ﹤0.01% | 2778 |
|
|
2024
Q2 | $10.6M | Sell |
280,126
-262,907
| -48% | -$11.1M | ﹤0.01% | 2418 |
|
|
2024
Q1 | $26.7M | Sell |
543,033
-72,189
| -12% | -$3.34M | ﹤0.01% | 1696 |
|
|
2023
Q4 | $22.5M | Buy |
615,222
+48,298
| +9% | +$1.26M | ﹤0.01% | 1754 |
|
|
2023
Q3 | $13.1M | Sell |
566,924
-31,082
| -5% | -$850K | ﹤0.01% | 2024 |
|
|
2023
Q2 | $15.7M | Buy |
598,006
+190,898
| +47% | +$5.02M | ﹤0.01% | 1897 |
|
|
2023
Q1 | $10.5M | Sell |
407,108
-42,819
| -10% | -$1.25M | ﹤0.01% | 2242 |
|
|
2022
Q4 | $11.7M | Buy |
449,927
+63,585
| +16% | +$1.57M | ﹤0.01% | 2116 |
|
|
2022
Q3 | $11M | Sell |
386,342
-140,487
| -27% | -$4.03M | ﹤0.01% | 2073 |
|
|
2022
Q2 | $13M | Buy |
526,829
+442,164
| +522% | +$16.2M | ﹤0.01% | 1952 |
|
|
2022
Q1 | $4.78M | Buy |
84,665
+62,298
| +279% | +$3.57M | ﹤0.01% | 3048 |
|
|
2021
Q4 | $1.39M | Buy |
22,367
+1,983
| +10% | +$131K | ﹤0.01% | 4143 |
|
|
2021
Q3 | $1.29M | Buy |
20,384
+518
| +3% | +$39.9K | ﹤0.01% | 4117 |
|
|
2021
Q2 | $1.64M | Buy |
19,866
+4,703
| +31% | +$357K | ﹤0.01% | 3938 |
|
|
2021
Q1 | $1.12M | Buy |
15,163
+4,309
| +40% | +$337K | ﹤0.01% | 4140 |
|
|
2020
Q4 | $788K | Buy |
10,854
+2,955
| +37% | +$190K | ﹤0.01% | 4102 |
|
|
2020
Q3 | $368K | Sell |
7,899
-8,615
| -52% | -$367K | ﹤0.01% | 4115 |
|
|
2020
Q2 | $694K | Buy |
16,514
+13,076
| +380% | +$465K | ﹤0.01% | 3711 |
|
|
2020
Q1 | $93K | Buy |
3,438
+34
| +1% | +$1.11K | ﹤0.01% | 4541 |
|
|
2019
Q4 | $131K | Buy |
+3,404
| New | +$79.7K | ﹤0.01% | 4815 |
|
Other funds holding SWTX
JP Morgan Chase's SWTX Position: Q3 2025 in Review
JP Morgan Chase sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 1,148,914 shares — an estimated $54M sold.
JP Morgan Chase first reported a position in SWTX in Q4 2019 and held it in 23 quarters. The position peaked at $54M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.
- JP Morgan Chase reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
- JP Morgan Chase sold 1,148,914 SpringWorks Therapeutics shares in Q3 2025, an estimated $54M.
- JP Morgan Chase first reported a position in SpringWorks Therapeutics in Q4 2019 and held it in 23 quarters.
- JP Morgan Chase's SpringWorks Therapeutics position peaked at $54M in Q2 2025.
- 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.
Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.